Becker's Healthcare September 25, 2024
On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen testified at a Senate committee hearing about the costs for Wegovy and Ozempic.
The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The former says the United States’ complex pharmaceutical industry — including pharmacy benefit managers — is causing high prices, while the latter says the drugmaker is acting on “corporate greed.”
During the hearing, Mr. Sanders said three major PBMs would increase Ozempic coverage if Novo Nordisk lowered the drug’s list price.
Wegovy is a weight loss medicine with a monthly list price of $1,349, and Ozempic is a Type 2 diabetes drug with a monthly list price...
Today's Sponsors
Today's Sponsor